Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why No One Cares About MannKind Corporation (MNKD)’s Earnings

Page 1 of 2

MannKind Corporation (NASDAQ:MNKD) announced earnings results on Monday, but no one cares. Don’t get me wrong. Plenty of people are intensely interested in MannKind. But do they really care one way or the other about the company’s earnings results? I don’t think so. Here’s why.

The results that didn’t matter
For the record, MannKind had $0 in revenue for the fourth quarter. That doesn’t bother anyone who follows the company, though. Many would have been surprised if the company reported a dime. MannKind did report $35,000 in revenue for the full year. That’s well below the median household income in the U.S., but no one cares.

MannKind Corporation (NASDAQ:MNKD)It lost around $51.8 million, or $0.23 per share. The loss is worse than the average analyst estimate of $0.18 per share. I doubt that any of them lift an eyebrow, much less downgrade the stock. Any analyst who believes in the prospects for MannKind won’t be phased by a nickel per share miss at this point in the game. And no one is worried about the $0.94 per share loss for the full year, either.

You might expect that some investors would care about the company’s cash situation. I’ll grant that some might. MannKind ended the quarter and year with $61.8 million in cash and equivalents, by the way. My guess, though, is that most shareholders didn’t sweat how much cash the company had. Thanks to CEO Alfred Mann’s efforts in the latter part of 2012, we knew that MannKind should be fine on the cash front for a while.

What really counts
Investors aren’t apathetic about MannKind, by any stretch of the imagination. It’s just that the earnings numbers don’t mean as much for the company as they do for most other publicly traded entities. What really counts for MannKind are the two phase 3 trials under way for Afrezza, the company’s inhalable insulin product.

The good news on that topic is that everything appears to be on track. The first study, which includes 518 patients with type 1 diabetes, is scheduled to finished in May. The second study, which includes 354 patients with type 2 diabetes, wraps up in June.  Mann noted that the trials have more patients than needed, which provides a cushion in case more patients than anticipated drop out.

MannKind expects to share results from both studies in August. The company is already working closely with the Food and Drug Administration on the planned resubmission of the New Drug Application, or NDA, for Afrezza. If all goes well, the NDA will be filed in late September or early October. That would likely translate to an FDA decision by the early second quarter of 2014.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!